AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23351820 — intervention group
Group type: COMPARATOR
Intervention: Synchronous clopidogrel + EC aspirin (81 mg) + EC omeprazole (40 mg)
Number of subjects: 30
Study 21995153 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta estradiol (HT group)
Number of subjects: 29
Study 21995153 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 19476991 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel titanium archwires
Number of subjects: 20
Study 19476991 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless steel archwires
Number of subjects: 20
Study 17672263 — intervention group
Group type: EXPERIMENTAL
Intervention: EC 40
Number of subjects: 47
Study 17672263 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervitec
Number of subjects: 47
Study 17672263 — intervention group
Group type: COMPARATOR
Intervention: ChemFil Varnish (control)
Number of subjects: 47
Study 14726370 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow up every three months
Number of subjects: 609
Study 14726370 — intervention group
Group type: COMPARATOR
Intervention: Follow up every six months
Number of subjects: 609
Study 11345371 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 516
Study 11345371 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty (PTCA)
Number of subjects: 516
Study 8989011 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg of 0.75% bupivacaine with 8.25% dextrose
Number of subjects: 8
Study 8989011 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg of 0.75% bupivacaine with 8.25% dextrose
Number of subjects: 8
Study 8989011 — intervention group
Group type: EXPERIMENTAL
Intervention: 11.25 mg of 0.75% bupivacaine with 8.25% dextrose
Number of subjects: 8
Study 8989011 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8
Study 7966066 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular gold
Number of subjects: 48
Study 7966066 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular methotrexate (MTX)
Number of subjects: 48
Study 7966066 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis with 15 patients already receiving DMARD treatment (n = 63)
Number of subjects: 48
Study 7966066 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with impaired functional capacity
Number of subjects: 48
Study 3495259 — intervention group
Group type: EXPERIMENTAL
Intervention: Touristil (C+D)
Number of subjects: 25
Study 3495259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine 40 mg (C)
Number of subjects: 25
Study 3495259 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 30 mg (D)
Number of subjects: 25
Study 3495259 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pl)
Number of subjects: 25
Study 29274242 — intervention group
Group type: EXPERIMENTAL
Intervention: Originator infliximab
Number of subjects: 25
Study 29274242 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosimilar CT-P13
Number of subjects: 25
Study 29274242 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25
Study 29274242 — intervention group
Group type: EXPERIMENTAL
Intervention: Both originator infliximab and biosimilar CT-P13
Number of subjects: 25
Study 26434404 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10mg/day
Number of subjects: 9991
Study 26434404 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg/day
Number of subjects: 9991
Study 25684963 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG + M
Number of subjects: 200
Study 23790235 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (155-195 U)
Number of subjects: 904
Study 23790235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 904
Study 20226302 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg, 10 mg, 20 mg
Number of subjects: 80
Study 20226302 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg, 10 mg, 20 mg
Number of subjects: 80
Study 20226302 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 20 mg
Number of subjects: 80
Study 20226302 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine 20 mg
Number of subjects: 80
Study 20226302 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing antihistamine doses
Number of subjects: 80
Study 19083400 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen-rich water (900 mL/d for 8 weeks)
Number of subjects: 36
Study 19083400 — intervention group
Group type: COMPARATOR
Intervention: Placebo pure water (900 mL/d for 8 weeks)
Number of subjects: 36
Study 16650535 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic combination therapy (n = 52)
Number of subjects: 105
Study 16650535 — intervention group
Group type: COMPARATOR
Intervention: Diluted epinephrine injection alone (n = 53)
Number of subjects: 105
Study 12934311 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 60
Study 12934311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10772522 — intervention group
Group type: EXPERIMENTAL
Intervention: Radially expanding needle system with blunt dilator
Number of subjects: 87
Study 10772522 — intervention group
Group type: COMPARATOR
Intervention: Sharp trocars
Number of subjects: 87
Study 10772522 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt dilator/cannula treatment
Number of subjects: 87
Study 8646654 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 336
Study 8646654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study 8646654 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 336
Study 8646654 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 336
Study 1334825 — intervention group
Group type: EXPERIMENTAL
Intervention: 125I‐labeled soluble insulin
Number of subjects: 12
Study 6391441 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% guanethidine‐0.5% epinephrine
Number of subjects: 40
Study 6391441 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% guanethidine‐0.2% epinephrine
Number of subjects: 40
Study 6391441 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol maleate
Number of subjects: 40
Study 31607641 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX
Number of subjects: 61
Study 31607641 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Number of subjects: 61
Study 31607641 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 61
Study 31607641 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line chemotherapy (overall)
Number of subjects: 61
Study 31072274 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-sling surgery
Number of subjects: 80
Study 31072274 — intervention group
Group type: COMPARATOR
Intervention: Transobturator tape
Number of subjects: 80
Study 31072274 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 28387882 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid-Collagenase applied once a day
Number of subjects: 113
Study 28387882 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle preparation)
Number of subjects: 113
Study 25822306 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% strontium dentifrice
Number of subjects: 28
Study 25822306 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% arginine dentifrice
Number of subjects: 28
Study 25822306 — intervention group
Group type: COMPARATOR
Intervention: Control (1,450 ppm NaF or water)
Number of subjects: 28
Study 23463411 — intervention group
Group type: EXPERIMENTAL
Intervention: FloSeal® (FS)
Number of subjects: 181
Study 23463411 — intervention group
Group type: COMPARATOR
Intervention: Bipolar electrocautery (EK)
Number of subjects: 181
Study 21165694 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS‐MPH
Number of subjects: 0
Study 21165694 — intervention group
Group type: COMPARATOR
Intervention: atomoxetine
Number of subjects: 0
Study 19661070 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme
Number of subjects: 149
Study 19661070 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational programme)
Number of subjects: 149
Study 17118648 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 1046
Study 17118648 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control)
Number of subjects: 1046
Study 17118648 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of necrosis
Number of subjects: 1046
Study 17118648 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathological evaluation
Number of subjects: 1046
Study 14728632 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol (1 microg daily for 36 weeks)
Number of subjects: 378
Study 14728632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study 11210070 — intervention group
Group type: EXPERIMENTAL
Intervention: Open flap debridement with enamel matrix derivative (EMD)
Number of subjects: 23
Study 11210070 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (control)
Number of subjects: 23
Study 9621836 — intervention group
Group type: EXPERIMENTAL
Intervention: Levels of processing (LOP) and selective attention during encoding
Number of subjects: 0
Study 9621836 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed study condition
Number of subjects: 0
Study 9621836 — intervention group
Group type: EXPERIMENTAL
Intervention: Shallow processing at test
Number of subjects: 0
Study 9621836 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective attention
Number of subjects: 0
Study 9621836 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention lag
Number of subjects: 0
Study 7942728 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate elixir (400 mg/5 ml per os every 8 h for three doses)
Number of subjects: 20
Study 7942728 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (no drug intervention)
Number of subjects: 20
Study 3069774 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesically administered Cetiprin (emepronium bromide)
Number of subjects: 40
Study 3069774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31525271 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue press method
Number of subjects: 21
Study 31525271 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasolacrimal occlusion (NLO)
Number of subjects: 21
Study 31525271 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 21
Study 31261779 — intervention group
Group type: EXPERIMENTAL
Intervention: Children who were underweight, wasted, or in anthropometric failure
Number of subjects: 893
Study 31261779 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunted children
Number of subjects: 893
Study 31261779 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight/obese children
Number of subjects: 893
Study 31261779 — intervention group
Group type: EXPERIMENTAL
Intervention: No anthropometric status indicator
Number of subjects: 893
Study 31261779 — intervention group
Group type: EXPERIMENTAL
Intervention: No demographic or socio-economic factor
Number of subjects: 893
Study 28866988 — intervention group
Group type: EXPERIMENTAL
Intervention: CIRCuiTS plus treatment‐as‐usual (TAU)
Number of subjects: 93
Study 28866988 — intervention group
Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 93
Study 24534756 — intervention group
Group type: EXPERIMENTAL
Intervention: MOR103 1.0 mg/kg
Number of subjects: 96
Study 24534756 — intervention group
Group type: EXPERIMENTAL
Intervention: MOR103 1.5 mg/kg
Number of subjects: 96
Study 24534756 — intervention group
Group type: EXPERIMENTAL
Intervention: MOR103 0.3 mg/kg
Number of subjects: 96
Study 24534756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 23406479 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly observed HAART delivered in methadone maintenance clinics
Number of subjects: 15
Study 21494285 — intervention group
Group type: EXPERIMENTAL
Intervention: Off axis retinoscopy
Number of subjects: 40
Study 21494285 — intervention group
Group type: COMPARATOR
Intervention: On axis retinoscopy
Number of subjects: 40
Study 19025276 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Web‐assisted tobacco intervention (Smoking Zine program)
Number of subjects: 1402
Study 19025276 — intervention group
Group type: COMPARATOR
Intervention: Interactive control condition task
Number of subjects: 1402
Study 16870009 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich food intake (measured through dietary records and urine samples)
Number of subjects: 53
Study 16870009 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fruits and/or fruit juices
Number of subjects: 53
Study 16870009 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee consumption
Number of subjects: 53
Study 16870009 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea and wine consumption
Number of subjects: 53
Study 14673606 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized omnivorous diet (OD) for 5 days
Number of subjects: 10
Study 14673606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovo-lacto-vegetarian diet (VD) for 5 days
Number of subjects: 10
Study 14673606 — intervention group
Group type: COMPARATOR
Intervention: Self-selected meat-containing diet (SD) for 2 weeks
Number of subjects: 10
Study 14673606 — intervention group
Group type: COMPARATOR
Intervention: Western-type diet (WD) for 5 days
Number of subjects: 10
Study 11002857 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0
Study 11002857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9350924 — intervention group
Group type: EXPERIMENTAL
Intervention: Thallium scintigraphy after 6 months of therapy
Number of subjects: 328
Study 9350924 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise electrocardiography after 6 months of therapy
Number of subjects: 328
Study 8250310 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with 1 mg/mL of meperidine
Number of subjects: 48
Study 8250310 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine without opioid (control)
Number of subjects: 48
Study 8250310 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with 3 micrograms/mL of fentanyl
Number of subjects: 48
Study 2870728 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimeprazine
Number of subjects: 85
Study 2870728 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam
Number of subjects: 85
Study 2870728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 29362903 — intervention group
Group type: EXPERIMENTAL
Intervention: RTXM83-CHOP
Number of subjects: 251
Study 29362903 — intervention group
Group type: COMPARATOR
Intervention: rituximab-CHOP
Number of subjects: 251
Study 26202528 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I BAV (right-left coronary cusp fusion)
Number of subjects: 67
Study 26202528 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I BAV
Number of subjects: 67
Study 26202528 — intervention group
Group type: COMPARATOR
Intervention: Control group (1000 patients with normal tricuspid aortic valve)
Number of subjects: 67
Study 25122601 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-length electrode array (26.4 mm)
Number of subjects: 13
Study 25122601 — intervention group
Group type: COMPARATOR
Intervention: Medium-length electrode array (20.9 mm)
Number of subjects: 13
Study 22634757 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast reaching movement
Number of subjects: 11
Study 22634757 — intervention group
Group type: COMPARATOR
Intervention: Slow reaching movement
Number of subjects: 11
Study 22634757 — intervention group
Group type: COMPARATOR
Intervention: Normal reaching movement
Number of subjects: 11
Study 22634757 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaching movement (general)
Number of subjects: 11
Study 20431041 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide LAR depot (up to 40 mg every 28+/‐5 days)
Number of subjects: 42
Study 20431041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 20431041 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 42
Study 18989221 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (15 sessions, individually delivered)
Number of subjects: 616
Study 18989221 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 616
Study 18989221 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 616
Study 16169793 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox-driven nebulization of albuterol labeled with Tc-99m DTPA
Number of subjects: 12
Study 16169793 — intervention group
Group type: COMPARATOR
Intervention: Air-driven nebulization of albuterol labeled with Tc-99m DTPA
Number of subjects: 12
Study 16169793 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox-driven nebulization
Number of subjects: 12
Study 16169793 — intervention group
Group type: COMPARATOR
Intervention: Air-driven nebulization
Number of subjects: 12
Study 12499817 — intervention group
Group type: EXPERIMENTAL
Intervention: Large volume paracentesis (LVP)
Number of subjects: 40
Study 12499817 — intervention group
Group type: COMPARATOR
Intervention: General management
Number of subjects: 40
Study 10071149 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic prednisolone treatment (group B)
Number of subjects: 22
Study 10071149 — intervention group
Group type: COMPARATOR
Intervention: Control group A
Number of subjects: 22
Study 7768760 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-amoxiclav 3.25 g single dose
Number of subjects: 666
Study 7768760 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole 960 mg bd for 7 days
Number of subjects: 666
Study 1983433 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloxazolam (4 mg/day)
Number of subjects: 837
Study 1983433 — intervention group
Group type: COMPARATOR
Intervention: Bromazepam (12 mg/day)
Number of subjects: 837
Study 622534 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza subunit vaccine
Number of subjects: 50
Study 622534 — intervention group
Group type: COMPARATOR
Intervention: Whole virus vaccine (control)
Number of subjects: 50
Study 31078511 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-automated CT software (QFAT 2.0, Cedars Sinai-Medical Center)
Number of subjects: 45
Study 31729959 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFM) program, commenced pre-operatively and continued for 12 weeks post-RP
Number of subjects: 97
Study 31729959 — intervention group
Group type: COMPARATOR
Intervention: Control group performing low-volume rehabilitation, commenced 5 weeks prior to surgery and continued for 12 weeks post-RP
Number of subjects: 97
Study 26691729 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivessel coronary artery disease
Number of subjects: 738
Study 26691729 — intervention group
Group type: COMPARATOR
Intervention: Single-vessel disease
Number of subjects: 738
Study 26691729 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic and electrocardiographic reperfusion success
Number of subjects: 738
Study 24748551 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 60
Study 24748551 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 60
Study 23502991 — intervention group
Group type: EXPERIMENTAL
Intervention: landiolol
Number of subjects: 200
Study 23502991 — intervention group
Group type: COMPARATOR
Intervention: digoxin
Number of subjects: 200
Study 21254007 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 57
Study 21254007 — intervention group
Group type: COMPARATOR
Intervention: Splenectomy
Number of subjects: 57
Study 19217738 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for quantification of losartan and losartan acid
Number of subjects: 0
Study 17420345 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose folic acid (400 microg/d)
Number of subjects: 56
Study 17420345 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose folic acid (5 mg/d)
Number of subjects: 56
Study 17420345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 15188836 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 600 microg orally administered immediately post-delivery
Number of subjects: 1600
Study 15188836 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered immediately post-delivery
Number of subjects: 1600
Study 12748111 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen-ozone therapy (4 mL intradiscal and 8 mL periganglionic injection at 27 micro g/mL)
Number of subjects: 600
Study 12748111 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oxygen-ozone therapy with corticosteroid and anesthetic injection
Number of subjects: 600
Study 10200751 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (maximum dose = 90 mg/day)
Number of subjects: 22
Study 10200751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 10200751 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 22
Study 7540062 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (250 micrograms/m2/d x 14 days)
Number of subjects: 47
Study 7540062 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF followed by G-CSF (5 micrograms/kg/d x 7 days)
Number of subjects: 47
Study 7540062 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 47
Study 7540062 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF followed by G-CSF
Number of subjects: 47
Study 2183866 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (4.0 g daily)
Number of subjects: 10
Study 2183866 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg daily)
Number of subjects: 10
Study 2183866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 385850 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealed cavities
Number of subjects: 0
Study 385850 — intervention group
Group type: COMPARATOR
Intervention: Open lesions
Number of subjects: 0